251 DNA and RNA alterations associated with colorectal peritoneal metastases: A systematic review Table 3. Continued Reference Level of Testing Name Genes, Molecules or Panel Investigated Type of Analysis Performed Gene or Molecule Name and Mutation or Expression Status (n) No. of Patients with PM (N) and Outcomes (n) No. of Patients without PM (N) and Outcomes (n) MMR Status (MSI/MSS) Findings as Reported by Authors in Studies Lan et al. 29 DNA TP53, APC, KRAS, FAT4, ARID1A, FBXW7, SMAD4, PIK3CA, NRAS and BRAF NGS N = 32 N = 63 For patients with PM, the frequency of genetic mutations was the highest in TP53. The authors conducted analysis to compare left- and right-sided CRC with mutation status but not between the non-PM and PM group. TP53 mutant (59) 19 40 KRAS mutant (35) 7 28 APC mutant (45) 17 28 Lee et al. 30 DNA Life Technologies Ion AmpliSeq Comprehensive Cancer Panel NGS N = 10 N = 5 N/A ARID1A, PKHD1, UBR5, PAX5, TP53, ASXL1 and AR were detected more frequently in the SOC group with PM (p values of 0.002, 0.019, 0.002, <0.001, 0.007, 0.047, 0.019 respectively d). TNFRSF14, VHL, MTRR, MLLT10, BIRC2, EP400, IRS2, PER1, TCF3 and CYP2D6 were detected more frequently in the LNOC group without PM (p values of 0.019, 0.004, 0.047, 0.022, <0.001, 0.022, <0.001, 0.022, 0.026, 0.004 respectively d). ARID1A mutant 9 0 PKHD1 mutant 7 0 UBR5 mutant 9 0 PAX5 mutant 10 0 TP53 mutant 8 0 ASXL1 mutant 8 1 AR mutant 7 0 TNFRSF14 mutant 5 3 VHL mutant 4 0 MTRR mutant 4 2 MLLT10 mutant 3 0 BIRC2 mutant 5 0 EP400 mutant 3 0 IRS2 mutant 5 0 PER1 mutant 3 0 TCF3 mutant 5 3 CYP2D6 mutant 4 0 11
RkJQdWJsaXNoZXIy MTk4NDMw